NUCLEOTIDE SEQUENCE ENCODING FUSED PROTEIN CONSISTING OF SOLUBLE EXTRACELLULAR FRAGMENT OF HUMAN Dll4 AND CONSTANT PART OF HEAVY CHAIN OF HUMAN IgG4 Russian patent published in 2022 - IPC C07K14/47 C07K19/00 C12N15/62 C12N15/63 C12N5/10 A61K47/68 

FIELD: biotechnology.

SUBSTANCE: invention relates to the field of biotechnology, specifically to the production of functional antagonists of human Delta-like ligand 4 (hereinafter – Dll4); it can be used for recombinant production of fused protein based on a soluble extracellular fragment of human Dll4, consisting of only DSL domain and domains of EGF-like repeats of Dll4 protein, placed in order corresponding to a natural sequence, and not including MNNL domain, and in this case the fragment Dll4 is connected to a constant part of a heavy chain of human IgG4.

EFFECT: invention provides obtainment of hybrid structures, which have only minimal effector function of antibody-dependent cell cytotoxicity, do not have complement-dependent cytotoxicity, and have relatively small molecular weight, which increases the efficiency of production of these molecules in mammalian cells and improves their properties related to a speed and efficiency of penetration into tissues; have decreased capability of aggregating and improved solubility, as well as provide effective blocking of Notch signaling due to the absence of MNNL domain in the structure.

18 cl, 2 dwg, 3 ex